Members Login
ACTG Network
  • Home
  • About
    • About the ACTG
    • Leadership and Organizational Matrix
    • ACTG Committees and Centers
    • Underrepresented Populations
    • Contact the LOC
  • Clinical Trials
    • About the Clinical Trials Process
    • Active Clinical Trials
    • Clinical Trials Resources
  • Sites
  • Community
    • Global Community Advisory Board
    • Community Resources
    • They Became My Family
  • Publications
  • News
    • COVID-19
    • Press Releases
    • Media Coverage
    • Network Spotlights
    • Newsletters
  • For Researchers
    • Submit a Proposal
    • Specimen Repository Website
    • HIV Databases

Case CRS

Location

Case Clinical Research Site
2061 Cornell Road
Room 401
Cleveland OH 44106

CRS Coordinator

Jane Baum

baum.jane@clevelandactu.org

216-844-2546

CRS Leader

Jeffrey M. Jacobson

jxj573@case.edu

215-707-6451

Studies
  • A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO)
  • A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV 
  • A5332: REPRIEVE Trial
  • A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults
  • A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants
  • A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
  • A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy
  • A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19
  • A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies
  • A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B

Mission

The mission of the ACTG Network
is to cure HIV and reduce the
burden of disease due to HIV
and its complications, including
tuberculosis and viral hepatitis.

Useful Links

Government Resources
Clinical Trials Resources
Grants and Contracts
New Members

© ACTG. All Rights Reserved. | admin login